Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review

10 Aug 2020

Abstract excerpt

OBJECTIVES: JDM is a rare autoimmune inflammatory muscle disease with a pronounced IFN signature. Treatment for children with JDM has improved over the years with the use of steroids and immunosuppressive agents. However, there remains a subset of children who have refractory disease. Janus kinase and type I IFN signalling production are suspected to contribute to the pathogenesis of JDM. Our pilot study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autoimmune and Inflammatory Disorders Research
Share to Inflammatory Myopathies and Dermatomyositis
Share to Spondyloarthritis Studies and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33024992
DOI: 10.1093/rheumatology/keaa558

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature reviewPMID 33024992Read ↗

Successful treatment of an anti-MDA5 antibody-positive Juvenile Dermatomyositis patient with refractory interstitial lung disease using tofacitinibSemantic proximity Read ↗

Current evidence for janus kinase inhibitors in adult and juvenile dermatomyositis and key comparisonsSemantic proximity Read ↗

Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositisSemantic proximity Read ↗

Recent advances in juvenile idiopathic inflammatory myopathies.Semantic proximity Read ↗

Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations.Semantic proximity Read ↗

Juvenile dermatomyositis: immunopathogenesis, role of myositis-specific autoantibodies, and review of rituximab use.Semantic proximity Read ↗

Effect of the Janus kinase inhibitor tofacitinib in the treatment of juvenile scleroderma: A single‐center experienceSemantic proximity Read ↗

Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care.Semantic proximity Read ↗

Update in juvenile myositis.Semantic proximity Read ↗

Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease.Semantic proximity Read ↗

Myositis-specific autoantibodies and their associated phenotypes in juvenile dermatomyositis: data from a German cohort.Semantic proximity Read ↗

The Significance of Autoantibodies in Juvenile Dermatomyositis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.